Prognostic effect of allogeneic hematopoietic stem cell transplantation on first and non-first complete remission in acute myeloid leukemia

Ning Hu, Zhiheng Cheng, Yifan Pang, Hongmian Zhao, Hui Ding, Li Chen, Qianyu Li, Yu Han, Tong Qin, Yifeng Dai, Yijie Zhang, Jinlong Shi, Depei Wu, Lin Fu


Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cure for intermediate or adverse-risk acute myeloid leukemia (AML) (1). It offers patients longer overall survival (OS) (2-4). Unfortunately, human leukocyte antigen (HLA) matched related donor is unavailable in more than 70% patients. Some of these patients, may experience relapse and subsequently achieve CR (non-CR1) with treatment. Some non-CR1 patients eventually receive allo-HSCT. It is unclear whether allo-HSCT will improve the survival of these patients.